CLINICAL TRIAL FACT SHEET

ClinicalTrials.gov Identifier: NCT01345019

Trial Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma.

Trial Description: An international, phase 3, randomized, double-blind, active controlled study comparing denosumab with zoledronic acid in newly diagnosed subjects with multiple myeloma.

Trial Objectives: to determine if denosumab is non-inferior to zoledronic acid with respect to the first occurrence of a skeletal related event (SRE) in subjects with multiple myeloma.

Assigned Interventions: Arm 1) Zoledronic acid 4mg (IV) & Placebo (SC) (Active comparator arm)

Arm 2) Denosumab 120mg (SC) & Placebo (IV) (Experimental arm)

Note: Daily supplementation of calcium ≥500mg and Vitamin D ≥400 IU is strongly recommended whilst on study.
Key Inclusion Criteria:

- Men and women ≥ 18 years old
- Documented evidence of multiple myeloma (per local assessment)
- Radiographic (i.e., X-ray or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
- Plan to receive or is receiving primary frontline anti-myeloma therapies
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate organ function
- Written informed consent
- Prior IV BP administration
- Ongoing dental/oral conditions and planned dental/oral procedures/surgery

Key Exclusion Criteria:

- Nonsecretory multiple myeloma (unless baseline serum free light chain level is elevated)
- Plasma cell leukemia
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- More than 30 days of previous treatment (before screening) with anti-myeloma therapy*
- Prior administration of denosumab
- More than 1 previous dose of IV bisphosphonate administration
- Use of oral bisphosphonates with a cumulative exposure of more than 1 year
- Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

* Does not include radiotherapy or a single short course of steroid

Recruiting Locations:

About 300 planned sites opening in the following countries:
Australia, Austria, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Lithuania, Malaysia, New Zealand, Poland, Portugal, Russia, Slovakia, Singapore, South Korea, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom and the United States.

If you’re interested in contacting an enrolling site or wish to refer a patient to an enrolling site, please see study site list at [www.MMBoneStudy.com](http://www.MMBoneStudy.com). If you’re unable to find a site in your region, please contact the IMF hotline 800-452-CURE (2873) for further information.